research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
Search
for
Sort by
Research
810-840 / 1000+ resultsresearch Structure of human steroid 5α-reductase 2 with anti-androgen drug finasteride
The research helps understand how finasteride works and aids drug development.
research Frontal Fibrosing Alopecia: To Treat or Not to Treat?
Treatments for Frontal Fibrosing Alopecia have not been proven effective.
research How to Select Pharmacologic Treatments to Manage Recidivism Risk in Sex Offenders: Consider Patient Factors When Choosing Off-Label Hormonal and Nonhormonal Agents
Choose treatments for sex offenders based on individual needs, using hormonal and nonhormonal options to reduce sexual drive.
research COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
research 5alpha-reductase inhibitors - a new hope in dermatology?
Finasteride shows promise for treating hair loss and excessive hair growth, but more research is needed to confirm its effectiveness and safety.
research The Latest Trends of Treatment for Alopecia
Finasteride, Dutasteride, and Minoxidil are effective for hair growth, while new treatments like laser therapy and PRP show promise with few side effects.
research Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
The updated integrated safety analysis of the ALLEGRO clinical trials evaluated the long-term safety of ritlecitinib in patients aged 12 years and older with alopecia areata over approximately 5 years. The study included 1,294 patients in the any-ritlecitinib group and 1,228 in the ritlecitinib 50 mg ± 200 mg group. Adverse events (AEs) were common, occurring in 87.1% of the 50 mg ± 200 mg group and 89.5% of the any-ritlecitinib group, with headache, positive SARS-CoV-2 test, and nasopharyngitis being the most frequent. Serious AEs were reported in 6.8% of patients in both groups. The incidence rates for opportunistic infections, herpes zoster, malignancies, and major adverse cardiovascular events were low. Overall, the safety profile of ritlecitinib was consistent with previous data, indicating it was generally well tolerated for long-term use in this patient population.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Finasteride for prostatic disease: an updated and comprehensive review
Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research A new label-free screen for steroid 5α-reductase inhibitors using LC-MS
Researchers developed a new method to find substances in herbs that can block a specific enzyme linked to hair loss.
research Evolution, classification, structure, and functional diversification of steroid 5α-reductase family in eukaryotes
Steroid 5α-reductase evolved from protists and diversified in eukaryotes, with specific roles in mammals and plants.
research Increasing utility of finasteride for frontal fibrosing alopecia
Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.
research Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
research An update of anti-viral treatment of COVID-19
As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
research II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
research Effective Treatment of Folliculitis Decalvans With a Combination of Oral Isotretinoin and Rifampicin
Combining oral isotretinoin and rifampicin effectively treats folliculitis decalvans.
research Sexual dysfunction associated with 5α-reductase inhibitors in the treatment of androgenetic alopecia: a systematic review
5α-reductase inhibitors for hair loss can cause mild, reversible sexual side effects in some men.
research Intermittent Low-dose Ritlecitinib in Refractory Paediatric Alopecia Areata: A Case Report with Therapeutic Implications
Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
research Carbon‐dioxide laser‐associated PDT treatment of folliculitis decalvans
CO2 laser-associated PDT effectively treated therapy-resistant folliculitis decalvans.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research Three Cases of Canine Dermatomyositis-Like Disease
Tailored treatment plans are crucial for managing canine dermatomyositis-like disease.
research Ritlecitinib (Litfulo)
Litfulo is recommended for treating severe alopecia areata in people 12 and older, as it helps hair regrowth.
research Phenytoin or Spironolactone Intervention Counteracts 5-Fluorouracil–Induced Alopecia in Rats by Suppressing Oxidative Stress and Inflammation While Promoting Collagen Synthesis
Phenytoin and spironolactone help prevent hair loss from chemotherapy by reducing stress and inflammation.
research Medikamentöse Therapie der BPH Ist eine Kombinationstherapie mit 5α-Reduktasehemmern und α-Rezeptorenblockern sinnvoll?
Combination therapy is more effective for prostate volumes over 60 ml.
![Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-Reductase Inhibitors](/images/assets/1634373b-f615-46c7-a157-21394e3366be/small/21095.jpg)
research Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-reductase inhibitors
Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
research Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses
Apremilast improved symptoms in patients with severe skin conditions.
research 1371 FGF7-dependent inhibition of human hair growth byan osteopontin-derived peptide: A novel solution for hirsutism and hypertrichosis?
A new peptide, FOL-005, may help treat excessive hair growth by reducing a hair growth promoter, FGF7.
research 保法止（非那雄胺）治疗雄激素性脱发
Finasteride can help regrow hair in male pattern baldness.